Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions - PubMed (original) (raw)

Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions

Ming Zhou et al. Am J Surg Pathol. 2002 Jul.

Abstract

alpha-Methylacyl-CoA racemase (AMACR) is a mitochondrial and peroxisomal enzyme involved in the metabolism of branched-chain fatty acid and bile acid intermediates. Recently, AMACR has been demonstrated to be over-expressed in localized and metastatic prostate cancer, suggesting that it may be an important tumor marker. This study examines AMACR expression in a variety of human cancers and their precursor lesions. A survey of online Expressed Sequence Tags (ESTs) and Serial Analysis of Gene Expression (SAGE) databases revealed that AMACR was over-expressed in multiple cancers. The findings were confirmed by AMACR immunohistochemistry performed on several tissue microarrays containing common human tumors, including prostate, colon, and breast. Based on prior work, AMACR protein expression was divided into two categories: negative (negative to weak staining intensity) and positive (moderate to strong staining intensity). AMACR protein over-expression was found in a number of cancers, including colorectal, prostate, ovarian, breast, bladder, lung, and renal cell carcinomas, lymphoma, and melanoma. Greatest over-expression was seen in colorectal and prostate cancer with positive staining in 92% and 83% cases, respectively. AMACR over-expression was present in 44% of breast cancer cases. AMACR was also over-expressed in precursor lesions. Sixty-four percent of high-grade prostatic intraepithelial neoplasia and 75% colonic adenomas demonstrated positive AMACR protein expression. Reverse transcriptase-polymerase chain reaction for AMACR using laser capture microdissected prostate tissue confirmed gene over-expression at the mRNA level. In conclusion, our study suggests that AMACR is potentially an important tumor marker for several cancers and their precursor lesions, especially those linked to high-fat diets.

PubMed Disclaimer

Cited by

Association of genetic variants of TMEM135 and PEX5 in the peroxisome pathway with cutaneous melanoma-specific survival.
Wang H, Liu H, Dai W, Luo S, Amos CI, Lee JE, Li X, Yue Y, Nan H, Wei Q. Wang H, et al. Ann Transl Med. 2021 Mar;9(5):396. doi: 10.21037/atm-20-2117. Ann Transl Med. 2021. PMID: 33842617 Free PMC article.
Phytanic acid and the risk of non-Hodgkin lymphoma.
Ollberding NJ, Aschebrook-Kilfoy B, Caces DB, Wright ME, Weisenburger DD, Smith SM, Chiu BC. Ollberding NJ, et al. Carcinogenesis. 2013 Jan;34(1):170-5. doi: 10.1093/carcin/bgs315. Epub 2012 Oct 5. Carcinogenesis. 2013. PMID: 23042099 Free PMC article.
Quantitative immunohistochemical detection of the molecular expression patterns in proliferative inflammatory atrophy.
Karaivanov M, Todorova K, Kuzmanov A, Hayrabedyan S. Karaivanov M, et al. J Mol Histol. 2007 Mar;38(1):1-11. doi: 10.1007/s10735-006-9070-5. Epub 2006 Dec 15. J Mol Histol. 2007. PMID: 17171435 Clinical Trial.
High frequency of the SDK1:AMACR fusion transcript in Chinese prostate cancer.
Zhang Y, Mao XY, Liu X, Song RR, Berney D, Lu YJ, Ren G. Zhang Y, et al. Int J Clin Exp Med. 2015 Sep 15;8(9):15127-36. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 26628996 Free PMC article.
Does the addition of AMACR to CK20 help to diagnose challenging cases of urothelial carcinoma in situ?
Alston ELJ, Zynger DL. Alston ELJ, et al. Diagn Pathol. 2019 Aug 16;14(1):91. doi: 10.1186/s13000-019-0871-8. Diagn Pathol. 2019. PMID: 31419984 Free PMC article.

Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions - PubMed (original) (raw)